分支链氨基酸作为自闭症患者的辅助替代治疗:试点研究
Despoina D Aspragkathou1, Martha G Spilioti2, Anastasia Gkampeta1
1Department of Pediatrics, Aristotle University of Thessaloniki, Medical School, Papageorgiou Hospital, Efkarpia, 56403Thessaloniki, Greece.
The British journal of nutrition
|July 10, 2023
概括
这项试点研究表明,分支链氨基酸 (BCAA) 补充剂可能会改善自闭症儿童的社交行为并减少多动性. 需要进一步的研究来证实这些初步发现用于自闭症管理.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 儿科 儿科 儿科
背景情况:
- 分支链氨基酸 (BCAA) 对于能量平衡和神经递质恒温是必不可少的.
- 在GABAergic,Glutamatergic,Serotonergic和Dopaminergic系统中的干扰与自闭症病理生理学有关.
- 在患有自闭症的人群中观察到低BCAA水平.
研究的目的:
- 研究BCAA补充剂作为自闭症行为儿童辅助疗法的疗效.
- 评估BCAA对儿童自闭症的社会行为,沟通和多动性的影响.
主要方法:
- 一项试点开放标签,前性研究,涉及55名自闭症行为儿童 (6-18岁).
- 每天服用0.4g/kg体重的无碳水化合物BCAA粉末 (白氨酸,异氨酸,氨酸).
- 每月进行心理评估,以监测随着时间的推移行为变化.
主要成果:
- 在55名参与者中,32人继续服用BCAA补充剂超过4周.
- 26名儿童 (47.27%) 接受BCAA超过10周的治疗,他们的社交互动,言语,合作,刻板印象和过度活跃度有所改善.
- 在研究期间没有报告任何不良反应.
结论:
- 初步证据表明,BCAA补充可能是治疗自闭症症状的有益辅助治疗方法.
- BCAA显示出改善自闭症儿童的社会行为和减少多动性的潜力.
- 需要进一步的临床试验来验证这些发现,并建立最佳的治疗方案.
相关概念视频
Autism Spectrum Disorder
161
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
161
Modeling in Therapy
124
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
124
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Attention-Deficit/Hyperactivity Disorder
132
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
132
Operant Conditioning Intervention
87
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
In operant conditioning, behaviors that are...
87
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
349
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
349


